Want to join the conversation?
Niche pharmaceutical company $AKRX posted 4Q15 net income of $32.78MM or $0.27 per diluted share vs. $17.98MM or $0.16 per diluted share in 4Q14. Revenues rose 38% to $0.28Bil vs. 4Q14, helped by higher gross profit results of $174.43MM. Total operating income also rose to $64.47MM during the quarter.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.
$VZ down more than 2% after a disappointing third quarter. A lot of uncertainty on the Yahoo deal too.